Thum will work with leaders across Juniper Square to accelerate sales velocity, strengthen and develop the company's brand ...

Results from the company’s Phase I trial found its prodrug, SPT-300, was well tolerated, opening the doors to a Phase IIb trial ...

PureTech Founded Entity Seaport Therapeutics Presents Additional Data from Phase 1 Study of SPT-300 at ACNP Annual Meeting ...

Australia: A recent study published in the New England Journal of Medicine highlighted the potential benefits of oral ...

Seaport Therapeutics (“Seaport” or the “Company”), a clinical-stage biopharmaceutical company that is advancing novel neuropsychiatric medicines with a proven strategy and team, today announced the ...